Coya Therapeutics, Inc. (COYA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the COYA SEC filings page.
Coya Therapeutics, Inc. (COYA) reported $8.0M in revenue over the twelve months to Jun 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Coya remains a development-stage business: revenue is growing, but rising R&D and administrative costs still widen annual losses.
From FY2023 to FY2025, revenue rose123.5% while the operating loss expanded30.8% , showing that increased activity has not yet produced operating leverage. Growth is therefore being accompanied by heavier spending rather than proportionately better cost absorption.
In FY2025, research and development reached
FY2025 financing inflows of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Coya Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Coya Therapeutics, Inc. held $46.8M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $10.7M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Coya Therapeutics, Inc. scores 68/100 among other emerging companies.
Coya Therapeutics, Inc. had 23M shares outstanding at the end of fiscal year 2025, against 17M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Coya Therapeutics, Inc. scores 28/100 among other emerging companies.
Coya Therapeutics, Inc. spent $16.7M on research and development in fiscal year 2025, which was 54.9% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Coya Therapeutics, Inc. scores 80/100 among other emerging companies.
Coya Therapeutics, Inc. reported revenue of $7.9M in fiscal year 2025, against $3.6M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Coya Therapeutics, Inc. scores 61/100 among other emerging companies.
Coya Therapeutics, Inc.'s operations used $10.7M of cash in fiscal year 2025, against $10.3M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Coya Therapeutics, Inc. scores 48/100 among other emerging companies.
Coya Therapeutics, Inc.'s cash, cash equivalents and investments came to $46.8M at the end of fiscal year 2025, against $6.9M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Coya Therapeutics, Inc. scores 92/100 among other emerging companies.
Coya Therapeutics, Inc. scores 8.06, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($116.1M) relative to total liabilities ($6.9M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Coya Therapeutics, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Coya Therapeutics, Inc. reported a net loss of $21.2M while operations used $10.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Coya Therapeutics, Inc. generated $244K in revenue in Q2 2026. This represents an increase of 49.0% from the same quarter a year earlier. Against the prior quarter it is down 2.9%.
Coya Therapeutics, Inc.'s EBITDA was -$7.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 9.9% from the same quarter a year earlier. Against the prior quarter it is up 7.8%.
Coya Therapeutics, Inc. reported -$6.6M in net income in Q2 2026. This represents a decrease of 8.9% from the same quarter a year earlier. Against the prior quarter it is up 7.9%.
Coya Therapeutics, Inc. earned -$0.28 per diluted share (EPS) in Q2 2026. This represents an increase of 22.2% from the same quarter a year earlier. Against the prior quarter it is up 12.5%.
Cash & Balance Sheet
Coya Therapeutics, Inc. held $43.2M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Coya Therapeutics, Inc.'s ROE was -15.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 6.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.6 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Coya Therapeutics, Inc. invested $5.0M in research and development in Q2 2026. This represents an increase of 37.3% from the same quarter a year earlier. Against the prior quarter it is up 22.8%.
Not reported for Q2 2026.
Not reported for Q2 2026.
COYA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $244K+49.0% | $251K-2.6% | $4.0M | $3.6M | $164K-95.2% | $258K+103.3% | N/A | $0 |
| R&D Expenses | $5.0M+37.3% | $4.1M-21.4% | $4.9M | $2.9M+31.2% | $3.7M-19.8% | $5.2M+66.2% | N/A | $2.2M+39.7% |
| SG&A Expenses | $2.3M-22.4% | $3.8M+39.4% | $3.3M | $2.6M+15.2% | $2.9M+39.3% | $2.7M+11.2% | N/A | $2.2M+13.0% |
| Operating Income | -$7.0M-9.9% | -$7.6M+0.5% | -$6.0M | -$2.4M+45.3% | -$6.4M-98.2% | -$7.7M-40.0% | N/A | -$4.5M-24.9% |
| EBITDA | -$7.0M-9.9% | -$7.6M+0.4% | -$6.0M | -$2.4M+45.4% | -$6.4M-98.4% | -$7.7M-40.1% | N/A | -$4.4M-24.9% |
| Income Tax | N/A | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
| Net Income | -$6.6M-8.9% | -$7.2M+1.4% | -$5.7M | -$2.1M+47.4% | -$6.1M-110.8% | -$7.3M-44.6% | N/A | -$4.0M-17.5% |
| EPS (Basic) | -$0.28+22.2% | -$0.32+27.3% | -$0.34-88.9% | -$0.13+50.0% | -$0.36-89.5% | -$0.44-25.7% | -$0.18-220.0% | -$0.26+23.5% |
| EPS (Diluted) | -$0.28+22.2% | -$0.32+27.3% | -$0.34-88.9% | -$0.13+50.0% | -$0.36-89.5% | -$0.44-25.7% | -$0.18-220.0% | -$0.26 |
| Diluted Shares (Avg) | 23M+40.3% | 23M+35.4% | N/A | 17M+9.9% | 17M+12.1% | 17M+15.7% | N/A | 15M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
COYA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $47.3M+41.4% | $53.3M+38.7% | $50.0M+12.6% | $32.0M-9.9% | $33.5M-16.2% | $38.4M+2.7% | $44.3M+7.5% | $35.6M+198.9% |
| Current Assets | $47.1M+40.8% | $53.3M+38.8% | $49.9M+12.7% | $32.0M-9.8% | $33.4M-16.2% | $38.4M+2.8% | $44.3M+7.6% | $35.5M+200.3% |
| Cash & Equivalents | $43.2M+45.1% | $50.7M+42.8% | $46.8M+22.1% | $28.1M-9.4% | $29.8M-18.6% | $35.5M-1.3% | $38.3M+17.5% | $31.1M+185.3% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $4.0M-21.6% | $4.3M-14.6% | $6.9M+45.1% | $4.8M+34.4% | $5.1M+9.8% | $5.0M+0.7% | $4.8M-15.2% | $3.5M+96.0% |
| Current Liabilities | $3.5M-22.0% | $3.5M-18.3% | $5.9M+53.5% | $3.7M+58.1% | $4.5M+17.7% | $4.3M+0.5% | $3.8M-24.3% | $2.3M+28.4% |
| Non-Current Liabilities | $520K-19.0% | $754K+8.6% | $1.1M+11.1% | $1.1M-10.7% | $641K-25.2% | $694K+1.9% | $945K+64.5% | $1.2M |
| Total Equity | $43.3M+52.9% | $49.0M+46.8% | $43.0M+8.7% | $27.3M-14.8% | $28.3M-19.7% | $33.4M+3.0% | $39.6M+11.1% | $32.0M+217.3% |
| Retained Earnings | -$75.8M-40.0% | -$69.2M-44.0% | -$62.0M-52.1% | -$56.3M-48.7% | -$54.1M-60.2% | -$48.0M-55.4% | -$40.7M-57.6% | -$37.8M-39.4% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
COYA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.4M-27.8% | -$6.2M-119.5% | -$1.0M+58.2% | -$1.1M+79.3% | -$5.8M-26.5% | -$2.8M-231.8% | -$2.4M-7.5% | -$5.5M-146.4% |
| Depreciation & Amortization | $3K-59.0% | $3K-59.0% | $7K0.0% | $7K0.0% | $7K0.0% | $7K0.0% | $7K0.0% | $7K0.0% |
| Stock-Based Compensation | $944K-8.9% | $2.2M+103.3% | N/A | $1.1M+38.2% | $1.0M+56.4% | $1.1M+147.9% | N/A | $775K+195.0% |
| Investing Cash Flow | -$2K | -$885K | -$649K | N/A | N/A | N/A | $0+100.0% | $0 |
| Financing Cash Flow | -$166K | $11.0M+57356.2% | $20.3M+110.0% | $19K+134.0% | $0-100.0% | $19K-98.5% | $9.7M-59.9% | -$56K |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
COYA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -2891.1% | -3042.1% | -152.3% | -68.3% | -3920.5% | -2976.9% | N/A | N/A |
| Net Margin | -2723.4% | -2869.6% | -144.2% | -59.4% | -3725.2% | -2833.3% | N/A | N/A |
| Return on Equity | -15.3%+6.2pp | -14.7%+7.2pp | -13.3% | -7.8%+4.8pp | -21.5%-13.3pp | -21.9%-6.3pp | N/A | -12.6%+21.4pp |
| Return on Assets | -14.0%+4.2pp | -13.5%+5.5pp | -11.4% | -6.6%+4.7pp | -18.2%-11.0pp | -19.0%-5.5pp | N/A | -11.3%+17.5pp |
| Current Ratio | 13.40+6.0x | 15.02+6.2x | 8.50-3.1x | 8.73-6.6x | 7.43-3.0x | 8.84+0.2x | 11.59+3.4x | 15.31+8.8x |
| Debt-to-Equity | 0.09-0.1x | 0.09-0.1x | 0.160.0x | 0.17+0.1x | 0.180.0x | 0.150.0x | 0.120.0x | 0.11-0.1x |
| Asset Turnover | 0.010.0x | 0.000.0x | 0.08 | 0.11+0.1x | 0.00-0.1x | 0.010.0x | N/A | 0.000.0x |
Not reported in any period shown, so not listed: Gross Margin, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Coya Therapeutics, Inc. COYA | FY2025 | $7.9M | -$21.2M | N/A | $116.1M | 63/100 |
| Connect Biopharma Holdings Limited CNTB | FY2025 | $64K | -$55.5M | N/A | $54.8M | — |
| TScan Therapeutics, Inc. TCRX | FY2025 | $10.3M | -$129.8M | N/A | $16.1M | 38/100 |
| MacroGenics, Inc. MGNX | FY2025 | $149.5M | -$75K | -0.1% | $238.2M | 57/100 |
| HilleVax, Inc. HLVX | FY2024 | N/A | -$147.3M | N/A | $104.8M | — |
| Oramed Pharmaceuticals Inc. ORMP | FY2025 | $2.0M | $75K | 3.8% | $180.1M | 51/100 |
Where Coya Therapeutics, Inc. Ranks
Frequently Asked Questions
What is Coya Therapeutics, Inc.'s annual revenue?
Coya Therapeutics, Inc. (COYA) reported $7.9M in total revenue for fiscal year 2025. This represents a 123.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Coya Therapeutics, Inc.'s revenue growing?
Coya Therapeutics, Inc. (COYA) revenue grew by 123.6% year-over-year, from $3.6M to $7.9M in fiscal year 2025.
Is Coya Therapeutics, Inc. profitable?
No, Coya Therapeutics, Inc. (COYA) reported a net income of -$21.2M in fiscal year 2025.
What is Coya Therapeutics, Inc.'s EBITDA?
Coya Therapeutics, Inc. (COYA) had EBITDA of -$22.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Coya Therapeutics, Inc.'s return on equity (ROE)?
Coya Therapeutics, Inc. (COYA) has a return on equity of -49.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Coya Therapeutics, Inc.'s operating cash flow?
Coya Therapeutics, Inc. (COYA) recorded an outflow of $10.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Coya Therapeutics, Inc.'s total assets?
Coya Therapeutics, Inc. (COYA) had $50.0M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Coya Therapeutics, Inc. spend on research and development?
Coya Therapeutics, Inc. (COYA) invested $16.7M in research and development during fiscal year 2025.
What is Coya Therapeutics, Inc.'s current ratio?
Coya Therapeutics, Inc. (COYA) had a current ratio of 8.50 as of fiscal year 2025, which is generally considered healthy.
What is Coya Therapeutics, Inc.'s debt-to-equity ratio?
Coya Therapeutics, Inc. (COYA) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Coya Therapeutics, Inc.'s return on assets (ROA)?
Coya Therapeutics, Inc. (COYA) had a return on assets of -42.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Coya Therapeutics, Inc.'s P/E ratio?
Coya Therapeutics, Inc. (COYA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $116.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Coya Therapeutics, Inc.'s price-to-sales ratio?
Coya Therapeutics, Inc. (COYA) trades at 14.5x sales, its market capitalization divided by revenue of $8.0M revenue, trailing 12 months to June 30, 2026. The market capitalization is $116.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Coya Therapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Coya Therapeutics, Inc. (COYA) held $46.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $10.7M over that year. Dividing the one by the other, the reported balance equals about 52 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Coya Therapeutics, Inc.'s Altman Z-Score?
Coya Therapeutics, Inc. (COYA) has an Altman Z-Score of 8.06, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Coya Therapeutics, Inc.'s Piotroski F-Score?
Coya Therapeutics, Inc. (COYA) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Coya Therapeutics, Inc.'s earnings high quality?
Coya Therapeutics, Inc. (COYA) reported a net loss of $21.2M while operations used $10.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Coya Therapeutics, Inc.?
Coya Therapeutics, Inc. (COYA) scores 63 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.